Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced its participation in the Society of Biomolecular Imaging and Informatics 1st Annual Conference (SBI2). Genedata will showcase Genedata Screener® for HCS, which supports a wide range of HCS systems and completely handles HCS analysis from cell-level data to final result reporting. Streamlining high content analysis, the solution provides instant and single-point image access throughout the HCS data analysis pipeline. The Genedata image management solution, which is part of Genedata Screener for HCS, will be featured in the SBI2 workshop – “Image Storage & Metadata Management Solution for Multiple Instruments and Diverse Image Analyses.” SBI2, a knowledge-sharing event for the global scientific community involved in High Content Analysis/High Content Screening (HCA/HCS), will be held at the Joseph B. Martin Conference Center, Harvard Medical School (Sept. 10-12).
HCA/HCS Innovations on Display at SBI2
“Biomolecular imaging and informatics are continually evolving and this first annual SBI2 conference will feature some of the world’s most innovative HCA and HCS research methodologies for drug discovery,” noted Mark Collins, a founding director of the Society for Biomolecular Imaging and Informatics. “The support of leading solution innovators such as Genedata helps SBI2 provide a high-value educational and scientific program at the conference and strengthens and grows the SBI2 community for the future.”
SBI2 will focus on HCA/HCS-related topics as practiced in basic research as well as drug discovery. Used by world’s leading pharmaceutical companies, academic institutions, and contract research organizations (CROs), Genedata Screener for HCS will be integral to these discussions. It is designed to manage all HCS data, easily handling complete assays with hundreds or thousands of plates with 5, 50 or 500 HCS features per well at single-cell resolution. The software imports all HCS features from HCS instrumentation, and integrates with major commercial and open-source HCS image and data management systems. As the single point of reference for downstream applications, it provides complete access to HCS data and images regardless of instrumentation, image store, image analysis software, or geographical location.
Genedata advancements in HCS image management and analysis will be presented as well at SBI2. The Genedata image management solution, which handles complex, heterogeneous environments with built-in workflow support and flexibility, will be featured in a workshop that will demonstrate how to:
“The SBI2 Conference gives leading researchers in HCA and HCS the opportunity to fully explore the latest innovations in drug discovery and basic research,” said Dr. Othmar Pfannes, CEO of Genedata. “As the platform of choice for all plate-based screening, Genedata Screener for HCS has become integral to the drug discovery process at leading pharma companies and CROs, and SBI2 provides an ideal forum in which researchers can speak to solution’s powerful analysis methods.”
Editorial Note: SBI2 Workshop “Image Storage & Metadata Management Solution for Multiple Instruments and Diverse Image Analyses” (Sept. 11; 12:00pm-12:45pm).
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial, and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US.
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.